title: Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
abstract: OBJECTIVE
  To evaluate the role of topical interferon alfa-2b (IFNalpha2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN).
  
  
  METHODS
  Noncomparative case series.
  
  
  METHODS
  Five patients with histologically proven CIN or recurrences of proven CIN were studied prospectively.
  
  
  METHODS
  After histologic confirmation, patients were given topical recombinant IFNalpha2b (INTRON A, Schering Plough, Kenilworth, NJ) 1 million IU/ml four times a day. Patients were continued on interferon until complete resolution of the tumor had occurred.
  
  
  METHODS
  Patients were followed clinically and photographically for evidence of tumor resolution.
  
  
  RESULTS
  All patients had complete resolution of the CIN lesion on IFNalpha2b. The mean time to clinical resolution was 11.6 weeks (range, 4-22 weeks). The mean follow-up was 17.6 months (range, 7-28 months). One patient had a clinical recurrence of his corneal CIN 1 year after tumor resolution. This patient was retreated, resulting in clinical resolution within 6 weeks, and has been tumor free for 8 months of follow-up.
authors.affiliation: Bascom Palmer Eye Institute, University of Miami, Miami, Florida 33136, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Karp
authors.forename: J K
authors.initials: JK
authors.lastname: Moore
authors.forename: R H
authors.initials: RH
authors.lastname: Rosa
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003316:Corneal Diseases / Q000188:drug therapy* / Q000473:pathology; D005134:Eye Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009883:Ophthalmic Solutions; D011994:Recombinant Proteins